HOME >> BIOLOGY >> NEWS
ESC Congress 2005 to utilise studies, sessions and sunshine to shed light on women and CVD

Sophia Antipolis, France, 21 June 2005: With the aim of better understanding and addressing women and cardiovascular disease (CVD), the European Society of Cardiology (ESC) has made women and CVD the focus of its next major annual event, the ESC Congress, which will take place in Stockholm, 3 7 September 2005.

The ESC Congress will highlight women and CVD by revealing results from the ESC Policy Conference and the ESC Euro Heart Survey during specific sessions at the Congress. The ESC also will provide information with regard to women and CVD during a two-day outdoor public event that will run alongside the ESC Congress, entitled 'For Your Heart's Sake,' 2 3 September 2005 in central Stockholm.

In preparation for the ESC Congress' focus, the ESC is convening a Policy Conference on 'CVD in Women' on 23 24 June 2005, which will bring together approximately 60 cardiologists and experts from the 49 ESC member countries to review and discuss medical literature on CVD in women. The group will evaluate the gap between scientific data and the perception about the role of CVD risk factors in women's health. Strategies will be discussed to promote research in the field of CVD in women and to educate both cardiologists and their patients. The results of this conference will be released during the ESC Congress 2005, and also through an article to be published in the European Heart Journal, an official journal of the ESC.

The ESC Congress' selection of sessions on women and CVD will include release of the Euro Heart Survey database analyses with incidence and treatment trends of women with CVD across Europe. Analyses of the Euro Heart Survey databases are expected to greatly contribute to an increased understanding and treatment of women and CVD through insight into manifestation, treatment and co-morbidity patterns in women compared to men.

There will also be a special focus on women and CVD, including specific information on risk factor reduc
'"/>

Contact: Gina Dellios
gdellios@escardio.org
33-492-948-627
European Society of Cardiology
21-Jun-2005


Page: 1 2 3

Related biology news :

1. AAAS analysis finds Congress would add billions to FY 2008 R&D investment
2. 2nd International EuroFIR Congress
3. Prize winners announced at ISNs World Congress of Nephrology
4. Nanotechnologys past, present and future: A Congressional perspective
5. Press registration -- World Congress of Nephrology, April 21-25, 2007, Rio de Janeiro, Brazil
6. Minister Lunn to speak at 10th National Forest Congress
7. Conservationist and actor Harrison Ford honored by Congressional Foundation
8. Q&A with Jeffrey Sachs on July 10 at Soils Congress
9. 18th World Congress of Soil Science
10. PITTs McGowan Institute for Regenerative Medicine presenting new research at World Congress
11. International Society of Nephrologys World Congress of Nephrology 2007

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
Breaking Biology Technology:
Cached News: